Hostname: page-component-848d4c4894-tn8tq Total loading time: 0 Render date: 2024-06-27T03:33:54.741Z Has data issue: false hasContentIssue false

Sodium Valproate in the Treatment of Cerebellar Disorders

Published online by Cambridge University Press:  18 September 2015

Andreas N. Neophytides*
Affiliation:
Experimental Therapeutics Branch, National Institute of Neurological and Communicative Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20014
Paul F. Teychenne
Affiliation:
Experimental Therapeutics Branch, National Institute of Neurological and Communicative Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20014
Ronald F. Pfeiffer
Affiliation:
Experimental Therapeutics Branch, National Institute of Neurological and Communicative Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20014
Donald B. Calne
Affiliation:
Experimental Therapeutics Branch, National Institute of Neurological and Communicative Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20014
*
Building 10, Room 6D20, National Institutes of Health, 9000 Rockville Pike, Bethesda, Maryland 20014, U.S.A.
Rights & Permissions [Opens in a new window]

Summary:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Because of the high concentrations of ɣ-aminobutyric acid (GABA) in the cerebellar cortex and nuclei, an attempt was made to enhance GABAergic transmission in patients with cerebellar disease. Maximum tolerated doses of sodium valproate, a drug which inhibits the degradation of GABA, failed to influence cerebellar deficits in a double blind crossover study on six patients.

Type
Research Article
Copyright
Copyright © Canadian Neurological Sciences Federation 1979

References

Bisti, S., Iosif, G., Marchesi, CF., and Strata, P. (1971). Pharmacological properties of inhibitions in cerebellar cortex. Exp. Brain Res., 14, 2437.CrossRefGoogle ScholarPubMed
Eccles, J., Ito, N., and Szentagothai, J. (1967). The Cerebellum as a Neuronal Machine. Springer: Berlin.CrossRefGoogle Scholar
Enna, S.J., Bird, E.D., Bennet, J.P., et al. (1976). Huntington’s Chorea. Changes in neurotransmitter receptors in the brain. N. Eng. J. Med., 295, 13051309.CrossRefGoogle Scholar
Fahn, S. and Cote, L.J. (1968). Regional distribution of gamma-aminobutyric acid (GABA) in brain of Rhesus monkey. J. Neurochem., 15, 209213.CrossRefGoogle ScholarPubMed
Hòkfelt, T., and Ljungdahl, A. (1975). Cerebral localization of labeled γamino-butyric acid (3H) - GABA in rat cerebellar cortex: an autoradiographic study. Brain Res., 88:295308.Google Scholar
Ito, M., Yoshida, M., Obata, K., et al. (1970). Inhibitory control of intracerebellar nuclei by the Purkinje cell axons. Exp. Brain Res., 10, 6480.CrossRefGoogle ScholarPubMed
Obata, K. (1976). Association of GABA with cerebellar Purkinje cells: single cell analysis. In GABA in Nervous System Function, edited by Roberts, E.Chase, T.N. and Tower, D.B. pp. 217222. Raven Press: New York.Google Scholar
Okata, Y., Nitch-Hassler, C, Kim, S.S., et al. (1971). Role of γaminobutyric acid (GABA) in the extrapyramidal motor system. 1. Regional distribution of GABA in rabbit, rat, guinea pig and baboon CNS. Exp. Brain Res., 13, 514.Google Scholar
Otsuka, M., Obata, K., Miyata, Y., and Tanaka, Y. (1971). Measurement of oy-aminobutyric acid in isolated nerve cells of cat central nervous system. J. Neurochem., 18, 287295.CrossRefGoogle ScholarPubMed
Perry, T.L., Berry, K., Hansen, S., et al. (1971). Regional distribution of amino acids in human brain obtained at autopsy. J. Neurochem., 18, 513519.CrossRefGoogle ScholarPubMed
Roberts, E. (1974). γ-Aminobutyric acid and nervous system function - A perspective. Biochem. Pharmacol., 23, 20372049.CrossRefGoogle ScholarPubMed
Sawaya, M.C.B., Horton, R.W. and Meldrum, B.S. (1975). Effects of anticonvulsant drugs on the cerebral enzymes metabolizing GABA. Epilepsia, 16, 549573.CrossRefGoogle ScholarPubMed